Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Homo sapiens | polymerase (DNA directed), beta | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma cruzi | mitochondrial DNA polymerase beta-PAK, putative | polymerase (DNA directed), beta | 335 aa | 303 aa | 32.3 % |
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | NEDD8 activating enzyme E1 catalytic subunit | 0.0793 | 1 | 0.5 |
Echinococcus multilocularis | NEDD8 activating enzyme E1 catalytic subunit | 0.0793 | 1 | 0.5 |
Plasmodium vivax | ubiquitin-activating enzyme E1C, putative | 0.0245 | 0.2504 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0192 | 0.1774 | 0.5 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta, putative | 0.0365 | 0.4136 | 1 |
Trypanosoma cruzi | ubiquitin activating enzyme, putative | 0.0245 | 0.2504 | 0.6055 |
Trichomonas vaginalis | ubiquitin-activating enzyme E1, putative | 0.0572 | 0.6973 | 1 |
Entamoeba histolytica | ubiquitin-activating enzyme, putative | 0.0793 | 1 | 0.5 |
Plasmodium falciparum | NEDD8-activating enzyme E1 catalytic subunit, putative | 0.0245 | 0.2504 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0192 | 0.1774 | 0.5 |
Trypanosoma brucei | NEDD8 activating enzyme subunit, putative | 0.0245 | 0.2504 | 0.3793 |
Leishmania major | ubiquitin activating enzyme, putative | 0.0245 | 0.2504 | 0.3793 |
Trypanosoma brucei | mitochondrial DNA polymerase beta | 0.0365 | 0.4136 | 1 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta, putative | 0.0365 | 0.4136 | 1 |
Trypanosoma cruzi | ubiquitin activating enzyme, putative | 0.0245 | 0.2504 | 0.6055 |
Toxoplasma gondii | NEDD8-activating enzyme E1 catalytic subunit | 0.0793 | 1 | 0.5 |
Loa Loa (eye worm) | ectopic membrane ruffles in embryo protein 1 | 0.0793 | 1 | 1 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta-PAK, putative | 0.0173 | 0.1507 | 0.3643 |
Schistosoma mansoni | ubiquitin-activating enzyme E1C | 0.0793 | 1 | 0.5 |
Leishmania major | mitochondrial DNA polymerase beta | 0.0365 | 0.4136 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 2.2387 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of DNA Polymerase Beta. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 3.5481 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 10.4179 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 22.3872 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.